A case of concomitant juvenile idiopathic arthritis (JIA) and paediatric-onset multiple sclerosis (POMS) – treatment with secukinumab and dimethyl fumarate followed by ofatumumab
More details
Hide details
Department of Neurology Medical University, Lublin, Poland
Corresponding author
Aleksandra Jartych   

Department of Neurology, Medical University, Jaczewskiego 8, 20-954 Lublin, Poland
J Pre Clin Clin Res. 2024;1(18):16-20
The aim of this case report is to highlight new possible treatment methods for concomitant juvenile idiopathic arthritis and multiple sclerosis in young patients. Promising results of using ofatumumab, secukinumab and dimethyl fumarate, both in the clinical case of a 22-year-old patient and mentioned literature, allows the belief that there is a chance for improving the quality of life of those who suffer from coexisting autoimmune diseases. However, it is crucial to perform further research in terms of the necessity and safety of the mentioned therapies, especially in the paediatric population, among whom there often exists difficulty in using treatment not registered for under-aged patients. Furthermore, the higher risk of side-effects caused by combined treatment of two autoimmune diseases should also be taken into consideration.
Jartych A, Jamróz-Wiśniewska A, Rejdak K, Kleszczyńska W, Kaczor M. A case of concomitant juvenile idiopathic arthritis (JIA) and paediatric- onset multiple sclerosis (POMS) – treatment with secukinumab and dimethyl fumarate followed by ofatumumab. J Pre-Clin Clin Res. 2024; 18(1): 16–20. doi: 10.26444/jpccr/185685
Landry RL, Embers ME. The Probable Infectious Origin of Multiple Sclerosis. NeuroSci. 2023;4(3):211–234.
Hennet T, Borsig L. Breastfed at Tiffany’s. Trends Biochem Sci. 2016;41(6):508–518.
De Silvestri A, Capittini C, Mallucci G, et al. The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. Dis Markers. 2019;2019:1409069.
Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun Rev. 2016;15(9):931–934.
Brenton JN, Kammeyer R, Gluck L, et al. Multiple Sclerosis in Children: Current and Emerging Concepts. Semin Neurol. 2020;40(2):192–200.
Jakimovski D, Awan S, Eckert SP, et al. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs. 2022;36(1):45–59.
Steinborn B. Stwardnienie rozsiane w wieku rozwojowym. In: Losy J, editor. Stwardnienie rozsiane. 2nd ed. Lublin; 2019. p. 233–255. Polish.
Chighizola CB, Ferrito M, Marelli L, et al. Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review. Biomedicines. 2022;10(8):2041.
Coşkun AN, Günbey C, Göçmen R, et al. Concurrence of juvenile idiopathic arthritis and primary demyelinating disease in a young child. Mult Scler Relat Disord. 2019;27:20–22.
Puszczewicz MJ, Tuchocka-Piotrowska A, Majewski D, et al. Przypadek współwystępowania młodzieńczego idiopatycznego zapalenia stawów i stwardnienia rozsianego. Ann Acad Med Stetin. 2006;52 Suppl 2:85–88. Polish.
Krawiec P, Batko B. Zastosowanie sekukinumabu w leczeniu pacjentów z łuszczycowym zapaleniem stawów i chorobami współistniejącymi. Forum Reumatol 2020;6(2):85–90.
Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582–590.
Blair HA. Secukinumab: A Review in Psoriatic Arthritis. Drugs. 2021;81(4):483–494. Erratum in: Drugs. 2021;81(6):735.
Eshwar V, Kamath A, Shastry R, et al. A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. Pharmaceuticals (Basel). 2022;15(11):1365.
Vermersch P, Scaramozza M, Levin S, et al. Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial. JAMA Netw Open. 2022;5(9):e2230439.
Saidu NEB, Kavian N, Leroy K, et al. Dimethyl fumarate, a two-edged drug: Current status and future directions. Med Res Rev. 2019;39(5):1923–1952.
Dello Russo C, Scott KA, Pirmohamed M. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. Pharmacol Ther. 2021;219:107710.
Liang G, Chai J, Ng HS, et al. Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2020;46:102566.
Di Tullio F, Odorici G, Lasagni C, et al. Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis. Dermatol Ther. 2020;33(6):e13943.
Vitale C, Falchi L, Ciccone M, et al. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol. 2020;11(1):19–23.
Bar-Or A, Wiendl H, Montalban X, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28(6):910–924.
Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546–557.
Kang C, Blair HA. Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis. Drugs. 2022;82(1):55–62. Erratum in Drugs. 2022;82(1):63.
Novartis Pharmaceuticals Corporation. KESIMPTA® (ofatumumab) injection, for subcutaneous use: US prescribing information. (accessed 2021.11.16).
Zaripova LN, Midgley A, Christmas SE, et al. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021;19(1):135.
Journals System - logo
Scroll to top